The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Selecting CAR-T bridging therapy for patients with ALL
Jae Park, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses considerations for selecting bridging therapy to CAR-T for patients with acute lymphoblastic leukemia (ALL). He highlights the importance of considering disease burden, prior therapies, and expected patient response. Dr Park also notes a shift away from intensive chemotherapy due to its toxicities. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Autolus Therapeutic, Genentech, Inc., Fate Therapeutics, Servier, Incyte, Takeda, Sobi; Consultancy: Curocell, Affyimmune, Amgen, Artiva Biotherapeutics, Bright Pharmacetuicals, Be Biopharma, BeiGene, Servier, Allogene, Intella, Takeda, Sobi, Pfizer, Kite, Minerva Bio, Synthekine; Current holder of stock options in a privately-held company: Artiva Biotherapeutics; Membership on Board of Directors or advisory committee: Artiva Biotherapeutics, Allogene, GC Cell.
